GALAPAGOS

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Galapagos' GLPG5101, a second-generation anti-CD19/4-1BB CAR-T therapy for relapsed/refractory mantle cell lymphoma.

Leap Therapeutics has announced a significant restructuring, reducing its workforce by approximately 50% and narrowing the development focus of its lead cancer drug candidate in response to challenging market conditions.

Belgian biotech Galapagos has abandoned its planned separation into two companies, citing unfavorable "regulatory and market conditions" that prompted a strategic reassessment.

Paul Stoffels will retire as Galapagos CEO within 12 months after three years at the helm, during which he transformed the company's focus to cell therapy and oncology through strategic acquisitions.

• Thad Huston, CFO and COO of Galapagos NV, will leave the company effective August 1, 2025, returning to the U.S. for personal and professional reasons. • During his two-year tenure since joining from Kite Pharma in 2023, Huston supported Galapagos' strategic transformation into a focused cell therapy company with a unique decentralized platform. • Galapagos expects to announce Huston's successor in the coming months, with the departing executive remaining until August to ensure a smooth transition of responsibilities.

Novo Nordisk undergoes significant executive restructuring following the departure of EVP Camilla Sylvest, with rare disease leader Ludovic Helfgott taking over expanded commercial strategy responsibilities.

Galapagos's lead CD19 CAR-T candidate GLPG5101 demonstrated compelling clinical results across three non-Hodgkin lymphoma indications, with complete response rates of 100% in MCL and 95% in MZL/FL.

Belgian biotech Galapagos will divide into two public companies, with SpinCo receiving €2.45 billion to pursue oncology, immunology, and virology opportunities through strategic transactions.

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.

Biopharma job postings declined 16% year-over-year in Q4 2024, with at least 24,000 industry professionals laid off throughout the year, including major cuts at Johnson & Johnson, Bristol Myers Squibb, and Bayer.